Background and Objective

This RAPTOR trial evaluates whether adding radiotherapy to patients with extensive‑stage small cell lung cancer (ES‑SCLC) who have previously received atezolizumab plus chemotherapy can extend progression‑free survival. Immunotherapy and radiotherapy operate via distinct mechanisms—immune activation and direct tumor cell cytotoxicity, respectively—supporting the potential for synergistic benefit.

Clinical Design and Primary Endpoints

The study employs a combined Phase II/Phase III design with progression‑free survival (PFS) and overall survival (OS) as co‑primary endpoints. Enrollment commenced on 7 January 2021 and remains ongoing. Patients are randomized to radiotherapy plus atezolizumab versus atezolizumab alone.

Current Treatment Landscape and Differentiation

The current standard of care for extensive‑stage SCLC is atezolizumab combined with chemotherapy. Radiotherapy has traditionally been reserved for localized progressive lesions, but it is now being investigated for integration into systemic therapy under the hypothesis that it can augment systemic immune responses. If successful, the combination could achieve greater tumor growth inhibition and survival benefit relative to existing regimens.

Expected Impact and Market Implications

Positive trial results could establish the immunotherapy‑radiotherapy combination as a new standard of care, driving growth in both the immune‑checkpoint inhibitor market and the radiotherapy equipment market, and creating a significant revenue expansion opportunity for companies that own atezolizumab.